<DOC>
	<DOCNO>NCT00708552</DOCNO>
	<brief_summary>The study design investigate efficacy , safety tolerability SB-742457 versus placebo subject mild-to-moderate Alzheimer 's disease . SB-742457 experimental treatment increase level certain chemical brain often decrease patient Alzheimer 's disease .</brief_summary>
	<brief_title>Study SB-742457 Donepezil Versus Placebo Subjects With Mild-to-moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Subjects caregiver must provide informed consent prior study entry . Subjects must clinical diagnosis probable mildtomoderate Alzheimer 's disease document 6month history AD symptom Subjects must regular caregiver willing attend visit , oversee subject 's compliance study report subject 's status . Female subject childbearing potential must agree pregnancy test approve form birth control . Exclusion criterion : Diagnosis possible , probable definite vascular dementia . History/evidence CNS disorder could interpret cause dementia History know suspected seizure , loss consciousness significant head trauma Subjects ECG , blood pressure laboratory value outside protocol criterion exclude . Subjects know photosensitivity Subjects history previous exposure SB742457 , take agent theoretical risk interaction SB742457 , take medication Alzheimer 's disease centrally act agent might impact study outcome may participate .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>SB-742457</keyword>
</DOC>